Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964642 | 0.97 | TDP1 (0.42) | TDP1MEN1FAAHMAPK1KMT2A | |
| Hexane SCHEMBL9763562 | 0.82 | TDP1 (0.57) | TDP1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL11217163 | 0.79 | — | — | |
| Hexane SCHEMBL9763768 | 0.79 | TDP1 (0.53) | TDP1MEN1FAAHMAPK1KMT2A | |
| Heptane SCHEMBL17938082 | 0.79 | TSHR (0.53) | TDP1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL27341055 | 0.78 | TDP1 (0.61) | TDP1 | |
| SCHEMBL9292699 | 0.78 | — | — | |
| SCHEMBL6369906 | 0.78 | TSHR (0.50) | TDP1MEN1KMT2ATSHRLMNA | |
| SCHEMBL811 | 0.78 | — | — | |
| Heptane SCHEMBL2515743 | 0.77 | TSHR (0.50) | TDP1MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103435619-B | A kind of Pochonicine analogue or its pharmacy acceptable salt and application thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-08-05 | — | — | CN | disclosed |
| CN-103435619-A | Pochonicine analogue or pharmaceutically acceptable salts of pochonicine analogue and application of pochonicine analogue or pharmaceutically acceptable salts of pochonicine analogue | CHINESE ACAD INST CHEMISTRY | 2013-12-11 | — | — | CN | disclosed |
| CN-102816144-A | Preparation method of star oligothiophene derivative | UNIV SOUTH CHINA TECH | 2012-12-12 | — | — | CN | disclosed |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| CN-101830846-A | Halogenated alkylthio pyridine derivate and preparation method thereof | OKEANOS TECH CO LTD | 2010-09-15 | — | — | CN | disclosed |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2048153-A1 | SUBSTITUTED SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
| CN-1241998-A | Synthesis of benzo (F) quinolinones | LILLY CO ELI (US) | 2000-01-19 | — | — | CN | disclosed |
| US-4598086-A | ANTIDERPRESSANTS; HYPERTENSIVE AGENTS | SYNTHELABO, (FR) | 1986-07-01 | — | — | US | disclosed |
| US-4567177-A | Imidazoline derivatives as α2 -antagonists | SYNTHELABO (FR) | 1986-01-28 | — | — | US | disclosed |
| US-4237300-A | CHEMICAL INTERMEDIATES FOR IMIDAZO(1,2-A)PYRIDINE ANTHELMINTIC AGENTS AS WELL AS BEING A FUNGICIDE | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4177274-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4146642-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4105767-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4096264-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | SLC5A1, SLC5A2, GCKR | TDP1 4561/4885MEN1 2235/4885FAAH 4673/4885 |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | SLC5A1, OR10J3, AKR1C3 | TDP1 4738/4885MEN1 1421/4885FAAH 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.